Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Animals
Antineoplastic Agents
/ administration & dosage
Caffeic Acids
/ administration & dosage
Cell Line, Tumor
Cisplatin
/ administration & dosage
Drug Delivery Systems
/ methods
Endopeptidases
/ biosynthesis
Endosomal Sorting Complexes Required for Transport
/ antagonists & inhibitors
Female
Humans
Mice
Mice, Nude
Ovarian Neoplasms
/ drug therapy
Phenylethyl Alcohol
/ administration & dosage
Ubiquitin Thiolesterase
/ antagonists & inhibitors
Xenograft Model Antitumor Assays
/ methods
CAPE (PubChem CID: 5281787°)
Cisplatin (PubChem CID: 2767)
Cisplatin resistance
Curcumin (PubChem CID: 969,516)
Deubiquitinases
Ferulic acid ethyl ester PubChem CID: 736681)
Ovarian carcinoma
USP8
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
21
10
2021
revised:
16
12
2021
accepted:
20
12
2021
pubmed:
8
1
2022
medline:
3
3
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Deubiquitinases (DUBs) mediate the removal of ubiquitin from diverse proteins that participate in the regulation of cell survival, DNA damage repair, apoptosis and drug resistance. Previous studies have shown an association between activation of cell survival pathways and platinum-drug resistance in ovarian carcinoma cell lines. Among the strategies available to inhibit DUBs, curcumin derivatives appear promising, thus we hypothesized their use to enhance the efficacy of cisplatin in ovarian carcinoma preclinical models. The caffeic acid phenethyl ester (CAPE), inhibited ubiquitin-specific protease 8 (USP8), but not proteasomal DUBs in cell-free assays. When CAPE was combined with cisplatin in nine cell lines representative of various histotypes a synergistic effect was observed in TOV112D cells and in the cisplatin-resistant IGROV-1/Pt1 variant, both of endometrioid type and carrying mutant TP53. In the latter cells, persistent G1 accumulation upon combined treatment associated with p27
Identifiants
pubmed: 34995485
pii: S0006-2952(21)00526-8
doi: 10.1016/j.bcp.2021.114900
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Caffeic Acids
0
Endosomal Sorting Complexes Required for Transport
0
Endopeptidases
EC 3.4.-
USP8 protein, human
EC 3.4.19.12
Ubiquitin Thiolesterase
EC 3.4.19.12
caffeic acid phenethyl ester
G960R9S5SK
Phenylethyl Alcohol
ML9LGA7468
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114900Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.